Meeting
2022 ASCO Gastrointestinal Cancers Symposium
NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
Authors
Charles D. Lopez
Oregon Health & Science University, Portland, OR
Charles D. Lopez , Adel Kardosh , Emerson Yu-sheng Chen , Skye C. Mayo , Robert Eil , Patrick Joseph Worth , Erin W. Gilbert , Flavio G. Rocha , Nima Nabavizadeh , Aaron Grossberg , Alexander Guimaraes , Bryan Foster , Brian Brinkerhoff , Shaun Goodyear , Erin Taber , Dove Keith , Jonathan Robert Brody , Gordon B. Mills , Rosalie Sears , Brett C. Sheppard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04539808
DOI
10.1200/JCO.2022.40.4_suppl.TPS630
Abstract #
TPS630
Poster Bd #
Q6
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.
First Author: Nai-Jung Chiang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FOLFIRINOX plus high intensity focused ultrasound for locally advanced/borderline resectable pancreatic ductal adenocarcinoma: A prospective single arm phase II trial.
First Author: Dong Ho Lee
Poster
2013 ASCO Annual Meeting
A phase I trial of a local delivery of siRNA against k-ras in combination with chemotherapy for locally advanced pancreatic adenocarcinoma.
First Author: Talia Golan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.
First Author: Derek B. Grose